Published in JAMA Intern Med on April 08, 2013
Relationship between surgical oncologic outcomes and publically reported hospital quality and satisfaction measures. J Natl Cancer Inst (2015) 1.50
Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer. J Oncol Pract (2015) 1.45
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02
Empiric vancomycin use in febrile neutropenic oncology patients. Open Forum Infect Dis (2014) 0.91
Patterns of use of hemostatic agents in patients undergoing major surgery. J Surg Res (2013) 0.88
Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. Gynecol Oncol (2015) 0.79
Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012. Clin Infect Dis (2016) 0.79
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med (2014) 0.78
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. Cancer Invest (2015) 0.75
Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. Cancer Invest (2016) 0.75
Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. Cancer Invest (2016) 0.75
The importance of evidence-based supportive care practice guidelines in childhood cancer-a plea for their development and implementation. Support Care Cancer (2016) 0.75
Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project. Contemp Oncol (Pozn) (2014) 0.75
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Surgeon volume and operative mortality in the United States. N Engl J Med (2003) 16.97
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Public reporting and pay for performance in hospital quality improvement. N Engl J Med (2007) 10.55
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis (2002) 7.81
Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA (2010) 6.89
Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med (2005) 6.65
Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med (2007) 6.51
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA (2010) 4.57
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer (2006) 3.78
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Hospital volume and late survival after cancer surgery. Ann Surg (2007) 2.93
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med (2011) 2.87
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer (2005) 2.25
Hospital volume and 30-day mortality for three common medical conditions. N Engl J Med (2010) 2.20
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
Volume, process of care, and operative mortality for cystectomy for bladder cancer. Urology (2007) 2.07
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 1.73
Cost of neutropenic complications of chemotherapy. Ann Oncol (2007) 1.50
Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes. J Oncol Pract (2011) 1.38
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst (2001) 1.15
Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother (2005) 1.14
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol (2008) 1.14
Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol (2011) 1.07
Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control (2006) 1.06
Epidemiology of febrile neutropenia. Support Cancer Ther (2003) 0.94
Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer (2001) 0.92
Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer (2007) 0.90
Success in implementing a hospital-wide evidence-based clinical pathways system for the management of cardiac patients: the ACAP program experience. Crit Pathw Cardiol (2011) 0.81
Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathways. Am Heart J (2008) 0.80
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Support Care Cancer (2008) 0.80
Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists. Oncol Rep (2005) 0.77
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol (1996) 0.77
Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol (2010) 4.43
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol (2007) 3.92
A proportional hazards model with time-dependent covariates and time-varying effects for analysis of fetal and infant death. Am J Epidemiol (2004) 3.77
Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst (2003) 3.71
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Previous cesarean delivery and risks of placenta previa and placental abruption. Obstet Gynecol (2006) 3.08
Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol (2005) 3.02
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Electronic fetal heart rate monitoring and its relationship to neonatal and infant mortality in the United States. Am J Obstet Gynecol (2011) 2.93
Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev (2002) 2.83
The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc (2011) 2.73
The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat (2002) 2.71
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Does augmentation or induction of labor with oxytocin increase the risk for autism? Am J Obstet Gynecol (2013) 2.68
Evaluation of third-degree and fourth-degree laceration rates as quality indicators. Obstet Gynecol (2015) 2.64
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Use of the Internet by women with breast cancer. J Med Internet Res (2003) 2.46
Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer (2006) 2.36
Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol (2008) 2.36
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat (2006) 2.26
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol (2006) 2.26
Prostate cancer in fathers with fewer male offspring: the Jerusalem Perinatal Study cohort. J Natl Cancer Inst (2007) 2.24
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Reconciling the high rates of preterm and postterm birth in the United States. Obstet Gynecol (2007) 2.21
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol (2011) 2.19
Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer (2009) 2.15
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Epidemiology of upper gastrointestinal malignancies. Semin Oncol (2004) 2.10
Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol (2011) 2.10
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Electric blanket use and breast cancer on Long Island. Epidemiology (2003) 2.06
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Placental abruption. Obstet Gynecol (2006) 2.05
Socioeconomic and other predictors of colonoscopy preparation quality. Dig Dis Sci (2010) 2.04
Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol (2005) 2.03
The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg (2013) 2.01
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol (2011) 2.00
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol (2010) 1.98
Trends and Predictors of Cerclage Use in the United States From 2005 to 2012. Obstet Gynecol (2015) 1.96
The influence of an audience response system on knowledge retention: an application to resident education. Am J Obstet Gynecol (2005) 1.96
Fear, anxiety, worry, and breast cancer screening behavior: a critical review. Cancer Epidemiol Biomarkers Prev (2004) 1.96
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med (2002) 1.89
Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol (2011) 1.86
Lifetime alcohol intake and breast cancer risk. Ann Epidemiol (2005) 1.85
Risk of malignancy in patients with celiac disease. Am J Med (2003) 1.85
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol (2008) 1.83
Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer (2005) 1.78
Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys (2006) 1.77
Risk factors of abruptio placentae among Peruvian women. Am J Obstet Gynecol (2006) 1.77
Induced Abortions and the Risk of Preeclampsia Among Nulliparous Women. Am J Epidemiol (2015) 1.76
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol (2009) 1.76
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol (2009) 1.75
Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.73
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology (2008) 1.71